These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10155317)

  • 1. The defined daily dose as a tool in pharmacoeconomics. Advantages and limitations.
    Clarke KW; Gray D
    Pharmacoeconomics; 1995 Apr; 7(4):280-3. PubMed ID: 10155317
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of pharmacoeconomics in health policy and management in Norway.
    Grund J; Husbyn H
    Pharmacoeconomics; 1995 Jun; 7(6):475-83. PubMed ID: 10155333
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin.
    Lopert R; Lang DL; Hill SR
    J Clin Pharm Ther; 2003 Jun; 28(3):243-9. PubMed ID: 12795784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics: determining the value of drug therapy.
    Peterson C
    Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
    [No Abstract]   [Full Text] [Related]  

  • 5. Providing cost-effective therapy using pharmacoeconomic evaluations: the public sector approach.
    Finder S
    Clin Ther; 1997; 19(1):160-6. PubMed ID: 9182021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of therapeutic drug monitoring in pharmacoeconomics.
    Destache CJ
    Ther Drug Monit; 1993 Dec; 15(6):608-10. PubMed ID: 8122303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of pharmacoeconomics in clinical management].
    Amat Díaz M; Poveda Andrés JL; Carrera-Hueso FJ
    Farm Hosp; 2011 May; 35 Suppl 2():18-24. PubMed ID: 22445505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of pharmaceuticals in critical care. The importance of outcome prediction models.
    Clifton GD; Blumenschein K
    Pharmacoeconomics; 1995 May; 7(5):388-92. PubMed ID: 10155326
    [No Abstract]   [Full Text] [Related]  

  • 9. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of pharmacoeconomics analyses to health protection].
    Drozd M
    Wiad Lek; 2002; 55 Suppl 1():76-9. PubMed ID: 15002222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the pharmacoeconomics of pharmacogenetics.
    Dervieux T; Bala MV
    Pharmacogenomics; 2006 Dec; 7(8):1175-84. PubMed ID: 17184205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency-based pharmacotherapy: the new paradigm for the 21st century in medicine.
    Soto J
    Eur J Clin Pharmacol; 2000 Nov; 56(8):525-7. PubMed ID: 11151740
    [No Abstract]   [Full Text] [Related]  

  • 14. A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.
    Garattini L; Grilli R; Scopelliti D; Mantovani L
    Pharmacoeconomics; 1995 Jan; 7(1):1-6. PubMed ID: 10155289
    [No Abstract]   [Full Text] [Related]  

  • 15. Indices of therapeutic outcome in pharmacoeconomic evaluation of drug therapy.
    Hurley SF
    Pharmacoeconomics; 1992 Mar; 1(3):155-60. PubMed ID: 10147026
    [No Abstract]   [Full Text] [Related]  

  • 16. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis.
    Dere W; Avouac B; Boers M; Buxton M; Christiansen C; Dawson A; Gennari C; Guillemin F; Lawaetz H; Ornskov F; Roumagnac I; Reginster JY
    Calcif Tissue Int; 1998 Aug; 63(2):93-7. PubMed ID: 9685510
    [No Abstract]   [Full Text] [Related]  

  • 17. Using pharmacoeconomics to value pharmacotherapy.
    Hay JW
    Clin Pharmacol Ther; 2008 Aug; 84(2):197-200. PubMed ID: 18679182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The costs of empiric and intuitive diagnoses. A critical evaluation of therapeutic trials and on unconventional practices].
    Piérard GE
    Rev Med Liege; 1998 May; 53(5):249-51. PubMed ID: 9689876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving efficacy, efficiency and economics of hospice individualized drug therapy.
    Lycan J; Grauer P; Mihalyo M; Houchen B
    Am J Hosp Palliat Care; 2002; 19(2):135-8. PubMed ID: 11926445
    [No Abstract]   [Full Text] [Related]  

  • 20. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Ann Pharmacother; 2006 Mar; 40(3):524-8. PubMed ID: 16507612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.